An official website of the United States government
Here's how you know
Official websites use .mil
A
.mil
website belongs to an official U.S. Department of Defense organization in the United States.
Secure .mil websites use HTTPS
A
lock (
lock
)
or
https://
means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.
Skip to main content (Press Enter).
Toggle navigation
JPEO-CBRND
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
JPEO-CBRND
Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):
Search
Search
Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):
Search
Home
About
Leadership
Joint Project Managers & Joint Project Leads
Our Story
Resources
Media
News
Photography
Work With Us
JETT - Joint Enterprise Technology Tool
SPARK
Careers
Contact
News
Results:
Archive:
February, 2022
DOD Awards Contracts to Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS’ One Billion Free At-Home COVID-19 Tests
February 18, 2022
— This week, the DoD, in coordination with HHS, awarded contract modifications to Roche Diagnostics Corporation and Siemens Healthineers purchasing a combined total of 138 million over-the-counter COVID-19 test kits. The JPEO-CBRND led this effort in partnership with DoD’s Defense Assisted Acquisition Cell (DA2), Army Contracting Command, and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). The procurement was funded through the American Rescue Plan Act to supply critical medical resources to the nation...
MORE
DOD Awards $250 Million Contract to Ology Bioservices, Inc., for Botulinum Monoclonal Antibody Advanced Development through FDA Licensure
February 10, 2022
— The JPEO-CBRND's Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) awarded Ology Bioservices, Inc. a $250 million sole source Federal Acquisition Regulation-based Indefinite Delivery/Indefinite Quantity (IDIQ) contract. Under the contract, Ology will advance the Botulinum Monoclonal Antibody (BOT MAB) product to U.S. Food and Drug Administration (FDA) licensure as a medical countermeasure (MCM), to protect the warfighter from exposure to botulinum neurotoxin (BoNT) A and B serotypes and to subsequently procure the FDA-licensed product...
MORE
News Search
News Archive - Search by Year and Month
2024 (33)
2023 (36)
2022 (31)
December (4)
November (1)
October (4)
September (5)
August (3)
July (3)
June (1)
May (1)
March (2)
February (2)
January (5)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)
JPEO-CBRND Press Kit
Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.
JPEO-CBRND Public Affairs Office
The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.